SS-31 peptide for mitochondrial dysfunction: what TikTok gets wrong

What's this video probably claiming?

Based on the caption and hashtag context, this creator is almost certainly positioning SS-31 (also called elamipretide or Bendavia) as a broad-spectrum fix for mitochondrial dysfunction, with the added suggestion that it amplifies the effects of other mitochondria-targeted peptides. The framing, "its job is to restore function from something that was dysfunctional," implies a corrective mechanism that applies across conditions, not just a narrow experimental context. The NAD+ hashtag alongside SS-31 suggests the creator may also be discussing synergy between SS-31 and NAD precursors or peptides, a stack that circulates heavily in longevity and biohacking communities. This is a research peptide with zero FDA approval for any indication, and the breezy educational framing here is doing a lot of heavy lifting to make that sound less significant than it actually is.

What does the science actually show?

SS-31 is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller, designed to selectively concentrate in the inner mitochondrial membrane and stabilize cardiolipin, a phospholipid that anchors electron transport chain complexes. Szeto et al. (2014, Biochimica et Biophysica Acta) demonstrated in animal models that cardiolipin stabilization reduced reactive oxygen species production and improved ATP synthesis efficiency. In a randomized controlled trial, Daubert et al. (2017, JACC: Basic to Translational Science) tested elamipretide in 36 patients with heart failure with reduced ejection fraction. After 4 weeks of daily subcutaneous injections, left ventricular end-systolic volume improved and exercise tolerance increased. Those are real signals. However, the PROGRESS-HF trial (Sabbah et al., 2020) showed mixed results in a larger cohort, with some endpoints not reaching significance. The gap between animal model promise and clinical reality is a recurring pattern here.

Where does the social media noise diverge from clinical reality?

The claim that SS-31 "makes other mito peptides better" is where the evidence gets extremely thin. There are no published human trials testing SS-31 in combination with other mitochondria-targeting compounds, including NAD precursors, MitoQ, or any peptide stack popular in the biohacking space. Synergy claims like this are extrapolated from in vitro or animal data, then laundered through influencer networks as established fact. The leap from "SS-31 improves mitochondrial function in isolated cardiomyocytes" to "stack it with your NAD peptide for maximum mito gains" is not a scientific inference. It is speculation dressed in the language of mechanistic biology. The creator's disclaimer, "not medical advice," does not change what is actually being communicated to 14,600 viewers about a compound that has never completed a Phase 3 trial for any indication.

What should you actually know?

SS-31 remains an investigational compound. The most rigorous human data comes from cardiovascular and renal ischemia-reperfusion contexts, not general wellness or anti-aging applications. Sloan et al. (2020, JCI Insight) showed elamipretide improved skeletal muscle mitochondrial function in older adults over 6 months, which is genuinely interesting. But the study enrolled 39 participants. That sample size does not support the sweeping mitochondrial dysfunction framing being applied here. Dosing used in trials has ranged from 0.005 to 0.25 mg/kg via subcutaneous injection, and adverse event profiles at higher doses are not fully characterized. If you are seeing SS-31 promoted for fatigue, long COVID, or general aging, know that these are off-label extrapolations from small trials in different patient populations. A physician specializing in this area is the appropriate starting point, not a TikTok caption.